InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) — FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A),…
Sweet Security Research Identifies Go Implementation of Node2Shell Vulnerability, Expanding Attack Surface to Major HTTP Frameworks
Savills Hong Kong Hosts Grand Reception to Celebrate 40th Anniversary
Micro-Dramas After 1 September 2026 – How China (Mainland) Rewrote the Rules
Hong Kong, Singapore, Tokyo: A Data Centre Comparison for Asian Site Selection